Connect with us

Health Care/Hospitals

Eisai to Present LENVIMA® (lenvatinib) and HALAVEN® (eribulin) Data in a Variety of Advanced Cancers at ESMO 2018 Congress

Vlad Poptamas

Published

on

Photo source: umcure2020.org
Reading Time: 3 minutes

 

– New data on tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer to be presented in oral Proffered Paper session on Monday, Oct. 22 at 3:09 p.m. CEST

 

Eisai Inc. announced today the presentation of six abstracts featuring data and analyses on its cancer treatments at the European Society of Medical Oncology (ESMO) 2018 Congress taking place in Munich from October 19-23. The results to be presented highlight new data for the company’s oncology agents, lenvatinib (marketed as LENVIMA®) and eribulin (marketed as HALAVEN®) for approved and investigational uses, respectively.

Presentations of interest include:

  • An oral presentation on tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer.
  • Correlative analyses of serum biomarkers and efficiency outcomes for lenvatinib, everolimus and the combination of these two agents in patients with metastatic renal cell carcinoma.
  • A final analysis of serum biomarkers from a Phase III study of lenvatinib vs. sorafenib in unresectable hepatocellular carcinoma.
  • Early results of a Phase Ib/II study on the combination of eribulin and PEGPH20 (PEGylated recombinant human hyaluronidase) in patients with HER2-negative, high hyaluronan metastatic breast cancer.

“Our data at ESMO include insights into the potential of lenvatinib and eribulin both as monotherapies and in combination with other agents across a variety of difficult-to-treat cancers,” said Alton Kremer, MD, PhD, Chief Clinical Officer and Chief Medical Officer, Oncology Business Group at Eisai. “As part of our human health care mission and dedication to patient access, we are committed to continually exploring ways to improve understanding of Eisai’s oncology treatments for the medical community and the patients impacted by these advanced cancers.”

This release discusses investigational compounds that are not Food and Drug Administration (FDA)-approved and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

The full list of Eisai presentations along with the time and location of each session is included below.

ABSTRACT NAME

SESSION (ALL TIMES ARE CEST)

Lenvatinib Abstracts (in collaboration with Merck)

Tumor growth rate and lenvatinib efficacy in 
radioiodine-refractory differentiated thyroid cancer

Presentation #1819O

Proffered Paper Session

Monday, October 22, 2018

3:09 p.m. – 3:33 p.m.

Location: Hall A1, Room 16

S. Leboulleux, MD

Correlative analyses of serum biomarkers and efficacy 
outcomes in the randomized, phase 2 trial of lenvatinib 
(LEN), everolimus (EVE) or LEN+EVE in patients with 
metastatic renal cell carcinoma

Presentation #76P

Poster Display Session

Saturday, October 20, 2018

12:30 p.m. – 1:30 p.m.

Location: Hall A3

C. H. Lee, MD, PhD

Final analysis of serum biomarkers in patients (pts) from 
the phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) 
in unresectable hepatocellular carcinoma (uHCC) 
[REFLECT]

Presentation #59PD

Poster Discussion Session

Saturday, October 20, 2018

3:00 p.m. – 4:00 p.m.

Location: Hall B4, Room 19

R. Finn, MD

Eribulin Abstracts

Eribulin as first- or second-line chemotherapy for 
advanced or metastatic HER2-negative breast cancer: a 
real-world prospective study

Presentation #314P

Poster Display Session

Monday, October 22, 2018

12:45 p.m. – 1:45 p.m.

Location: Hall A3

M. Takahashi, MD

Early Results from an Open-label Phase 1b/2 Study of 
Eribulin Mesylate (EM) + Pegvorhyaluronidase Alfa 
(PEGPH20) Combination for the Treatment of Patients 
(Pts) with HER2-Negative, High-Hyaluronan (HA) 
Metastatic Breast Cancer (MBC)

Presentation #311P

Poster Display Session

Monday, October 22, 2018

12:45 p.m. – 1:45 p.m.

Location: Hall A3

M. Shum, MD

Economic Evaluation of Eribulin in the Treatment of Triple 
Negative Breast Cancer in the United Kingdom

Presentation #348P

Poster Display Session

Monday, October 22, 2018

12:45 p.m. – 1:45 p.m.

Location: Hall A3

J. Wex, MD, PhD

In March 2018, Eisai and Merck (known as MSD outside of the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

 

Hello!


Thank you for visiting my profile and thank you for reading my news and published press release!


There a many things that shape a man, but the carving is done by the hobbies and passions. I've pursued two main careers, professional photography and webdesign, while also keeping a passion for automobiles, technology and games. At PICANTE NEWS, I take care of news editing and press release publishing in se
veral categories and as I've mentioned, during my spare time, I am also a professional photographer with webdesign skills.

My future plans include developing more journalistic skills and start creating investigative journalism. You can find my reports and press release coverages in the following categories:


BANKING/FINANCIAL SERVICES, COMPUTER ELECTRONICS, AUTOMOTIVE, CONTRACTS, ANALYSIS, INTERNET TECHNOLOGY, BIOTECHNOLOGY, BLOCKCHAIN, ACQUISITIONS, RETAIL, and many more.



You can get in touch to discuss interviews or possible article submissions via e-mail on vlad@picante.today or call our office number: 0040 731 394 220.


Let's also connect via social media! You can find me on Facebook or visit my photo portfolio.

Advertisement
Comments

Health Care & Hospital

Cipla and Wellthy Therapeutics Announce Partnership to Offer Digital Therapeutics for Diabetes and Cardiovascular Diseases

Vlad Poptamas

Published

on

CONTACT: Media contact: Cipla Limited: Corporate Communications: Heena Kanal, E-mail: CorpComm@cipla.com; Investor Relations: Naveen Bansal, E-mail: Investor.Relations@cipla.com; Reshma Nayak, reshma.nayak@wellthy.care, corpcomm@wellthy.care, +91-9137603901
Reading Time: 2 minutes

 

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereafter referred to as “Cipla”) and Wellthy Therapeutics Private Limited(“Wellthy Therapeutics”) today announced that they have entered into a partnership to offer a combination of pharmacotherapy and digital therapeutics for improved patient outcomes in the chronic therapies of Diabetology and Cardiology.

Under the agreement, a multi-lingual clinically-validated digital disease management platform will be made available to patients living with diabetes or cardiovascular diseases via doctors’ clinics or co-packaging on select Cipla brands. The platform brings together behavioral science, real-world clinical evidence and artificial intelligence to provide real-time monitoring, coaching and advice to patients, and virtual clinical assistance to doctors.

This partnership is a result of Cipla’s campaign, Innoventia, which was envisioned as a first-of-its-kind challenge by an Indian pharmaceutical company to encourage innovation-led entrepreneurship and to harness disruptive ideas in healthcare to fulfil unmet patient needs.

Umang Vohra, MD & Global CEO of Cipla, said, “The future of healthcare will be driven by increased use of technology, and this partnership gives Cipla the ability to offer this combination of prescription drugs and artificial intelligence-powered digital therapeutics to patients in cardio-metabolic health. It will allow patients to make informed decisions and take charge of their own health. By pairing our pharmacotherapy strengths with the digital approach to healthcare taken by Wellthy Therapeutics, Cipla will add to its diversified portfolio in the cardio-metabolic area to provide holistic care to patients from awareness, diagnosis and compliance to wellbeing.”

Abhishek Shah, Co-founder & CEO of Wellthy Therapeutics, said, “We are excited to work with Cipla to bring digital therapeutics to patients in India. Companion digital therapeutics are redefining the treatment of chronic conditions, by helping personalize and simplify disease management for patients and driving precision clinical insights to clinicians. With the combination of Cipla’s world-class formulations and clinically-validated digital therapeutics of Wellthy Therapeutics, we look forward to helping empower and inspire millions of patients to achieve better sustainable health outcomes.”

 

SOURCE Wellthy Therapeutics

Continue Reading

Computer Electronics

Seismic Named to Fast Company’s Annual List of the World’s Most Innovative Companies

Vlad Poptamas

Published

on

Seismic's activewear features discreet robotic muscles that lay over quad muscles, each hip, and the lower back, helping people with core strength and wellness.
Reading Time: 2 minutes

 

Seismic, an apparel company whose signature line of Powered Clothing™ features discreet robotic muscles, proudly announces that it has been named to Fast Company’s prestigious World’s Most Innovative Companies for 2019. The annual list, released today, spotlights “businesses making the most profound impact on both industry and culture.” Seismic earned the No. 8 standing in the global robotics category.

Now in its eighth year, the award received the most competitive field of nominees in its history, according to Fast Company. More than three dozen editors, reporters and contributors assessed thousands of company applications and narrowed their selections to a prestigious Top 10 list of the Most Innovative Companies by sector, from advertising to wellness. The jury considered the impact each company offered in both their industry and culture at large.

Seismic is forging a new path for wearable robotics through activewear that is stylish, lightweight and comfortable, with low-profile, robotic muscle technology. Last September, Seismic unveiled its Spring 2019 apparel collection of Powered Clothing on stage at TechCrunch Disrupt, which is the world’s largest technology startup conference. Designed to support core wellness, the garment augments human strength for the everyday consumer who wants to enhance core strength and posture. The bespoke suits have robotic components that provide up to 30 watts of power to each hip and the lower back to support daily activities — like sitting, standing, lifting, or carrying — and give people a physical advantage in their personal lives.

“We’re honored to be recognized by the seasoned team at Fast Company,” said Rich Mahoney, Seismic CEO and Co-founder. “Seismic opens up a new functionality to apparel – one powered by robotics – while maintaining our relationship with clothing in terms of comfort, aesthetic, and emotion. We see a future where simply getting dressed in the morning can dramatically improve people’s lifestyles and expand what they are capable of accomplishing. I congratulate our world-class expert team at Seismic who have taken on an audacious mission to shape the future of clothing and am thrilled to receive this ranking from one of the leading publishers in business, design and innovation.”

The World’s Most Innovative Companies is Fast Company’s signature franchise and one of its most highly anticipated editorial efforts of the year. The awards provide both a snapshot and a road map for the future of innovation across the most dynamic sectors of the economy. Fast Company’s Most Innovative Companies issue is now available online and will be on newsstands beginning February 27.

For more information about Seismic, click here for a company fact sheet or click here for digital assets.

 

SOURCE Seismic

Continue Reading

Health Care & Hospital

Access to Affordable Medical Care and National Health Protection Scheme, Priority of Government: D V Sadananda Gowda

Vlad Poptamas

Published

on

Photo source: chespenn.org
Reading Time: 3 minutes

 

  • Steps afoot to make pharmaceuticals a Rs 3 lakh crore market
  • Opportunity for Industry through Ayushman Bharat Programme
  • Technologies like AI and advanced analytics being increasingly adopted by pharmaceutical industry: FICCI-KPMG Knowledge Paper

Mr D V Sadananda Gowda, Minister of Chemicals and Fertilizers, Statistical and Programme Implementation, Government of India, said here today that the Government’s focus was on improving access to affordable medical care and contribute to the National Health Protection Scheme, even as India continues to maintain its leadership position in manufacturing and supply of high-quality generic medicines.

Mr Gowda was speaking at the 4th International Conference on Pharmaceuticals and Medical Devices organized by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India jointly with the Federation of Indian Chambers of Commerce & Industry (FICCI).

Mr Mansukh L. Mandaviya, Minister of State for Chemicals & Fertilizers, Road Transport and Highways, Shipping, Government of India, while stressing on the development of infrastructure and affordable healthcare through initiatives like Ayushman Bharat, said that the Government was taking measures to make the Indian pharmaceutical sector a Rs. 3 lakh crore market.

Mr K J George, Minister for Large & Medium Scale Industries, Government of Karnataka, said that the state government plans to set up a special pharmaceuticals SEZ in Hassan and Pharma Parks in Bengaluru and Mangalore, which forms a part of the Government of India’s aim of investing over USD 50 billion by 2025.

Dr Henk Bekedam, WHO Representative to India,  stated that considering the increased involvement of the micro, small & medium enterprises in the medical devices manufacturing sector, WHO will provide technical support to the sector to upgrade manufacturing standards.

Mr S Sridhar, Chairman, FICCI Pharma Committee said that industry believed in universal healthcare at affordable price for all Indian citizens, adding that this is a long-term plan and requires a joint effort of the government, industry and other stakeholders to collectively own this vision.

Mr Badhri Iyengar, Chairman, FICCI Medical Device Forum, said that it was important to look at having a unified healthcare regulator which could act as a bridge between the industry and the government to create one window for facilitating business.

Drug regulators from over 30 countries including RussiaKenya, the UK, MalaysiaIndonesia, Saudi Arabia and Uzbekistan participated in the event. The event also saw participation of drug regulators from 15 states across India.

A FICCI-KPMG Knowledge Paper ‘Evolution to revolution: by use of Artificial Intelligence and Advanced Analytics in pharma’ was also released at the event.

Highlights of FICCI-KPMG Knowledge Paper ‘Evolution to revolution: by use of Artificial Intelligence and Advanced Analytics in pharma’

  • Catalyzed by an exciting range of new, disruptive technologies, the pharmaceutical industry needs to reimagine its future. And the need to reimagine is being driven by shifts which are disturbing the industry’s status quo – pressure to reduce costs and demonstrate greater value, swing from treatment to prevention, and personalized treatments. These shifts are challenging the overall business model of the pharmaceutical companies
  • Emerging technologies, AI and advanced analytics are being increasingly adopted by the pharmaceutical industry in many diverse and interesting ways
  • The value of technologies comes from their ability to process large amounts of complex, both structured and unstructured data, at a rapid pace to generate actionable insights and thereby reduce costs, improve time to market and gain competitive strength in the marketplace
  • While a lot of interesting applications are in areas related to drug discovery, applications in other areas such as drug dosage and safety, manufacturing and supply chain and commercialization is being further explored
  • As far as technologies are concerned, pharmaceutical companies are choosing their fields of play and also who they play with, with a growing emphasis on collaboration and partnership. Accordingly, the industry is witnessing many such partnerships and quite often with technology start-ups

Please see the link below for knowledge report: https://we.tl/t-VacA7NGXt4

 

SOURCE Federation of Indian Chambers of Commerce & Industry (FICCI)

Continue Reading

Font Resizer

Subscribe to PICANTE via Email

Enter your email address to subscribe to PICANTE and receive notifications of new posts by email.

Follow us on Facebook

Read more from our authors

Entertainment5 hours ago

ZEE5 and Dialog Announce a Strategic Partnership to Bring the Largest Bouquet of Premium Regional Content to Sri Lanka

Airlines/Aviation 5 hours ago

Excitech to Deliver Common Data Environment to Heathrow Airport Limited

Contracts5 hours ago

The “Calligraphy, Tea Culture and Silk Road Photography” Sino-Singaporean cultural exchange event takes place in Singapore

Computer Electronics5 hours ago

Polystar’s Enhanced 5G Core Network Testing Capabilities Help CSPS on Road to Commercial Deployment

Banking & Financial Service5 hours ago

LGT opens wealth management office in Thailand for high net worth investors

Asia5 hours ago

Nielsen Launches SMARTSTORE in Hong Kong

European Commission Press Releases6 hours ago

Statement by Commissioner Jourová ahead of the European Day for Victims of Crime

European Commission Press Releases6 hours ago

Structure of orchards in 2017 – Two-thirds of the EU’s fruit plantation area is concentrated in Spain, Italy and Poland

European Commission Press Releases6 hours ago

State aid: Commission opens in-depth investigation into British Capacity Market scheme

Latest News6 hours ago

MYCOM OSI Demonstrates End-to-End Assurance for Red Hat virtual central office solution

Corporate Expansion6 hours ago

Federal Signal Announces Plans to Expand Illinois Manufacturing Facility to Support Increased Demand

Asia6 hours ago

Indonesian Digital Infrastructure Provider Alterra Deploys Vymo Sales CRM to Grow Channel Partner Business

Computer Electronics6 hours ago

University of New Haven Researchers Discover Critical Vulnerabilities in Popular Virtual Reality Application

Latest News6 hours ago

VRtuoso Secures $650,000 to Extend VR Enterprise Training to All Companies

Canada7 hours ago

NexTech Launches ‘Try-It-On’ Augmented Reality Experience for Online Retail

Latest News7 hours ago

Belfast Tech Startup Using Automated Lip-Reading to Make User Authentication Systems More Resistant to Spoofing Attacks

Awards7 hours ago

The BBVA Foundation recognizes Ivan Sutherland for revolutionizing human-machine interaction through computer graphics and virtual reality

Automotive7 hours ago

Best New Automotive Innovations for 2019 Announced by Automobile Journalists Association of Canada

Health Care & Hospital7 hours ago

Cipla and Wellthy Therapeutics Announce Partnership to Offer Digital Therapeutics for Diabetes and Cardiovascular Diseases

Computer Electronics8 hours ago

Seismic Named to Fast Company’s Annual List of the World’s Most Innovative Companies

Automotive8 hours ago

Karma Automotive Bolsters Growing Leadership Ranks

Advertising8 hours ago

Vibes Unveils Conversational Analytics, The Industry’s First Natural Language Processing Solution

Latest News8 hours ago

New Study: 7 in 10 women make significant financial sacrifices for the sake of others

Banking/Financial Services9 hours ago

BizClik Media Announces the Launch of FinTech Magazine

Computer Software9 hours ago

Infosys Recognized Among the Top Three Employers in Europe and Middle East

Latest News2 weeks ago

Rolls Royce and Tudor Tech sign up to the Defence Aviation Safety Conference

African American2 weeks ago

Alfred Street Baptist Church Awards Howard University $100K To Pay Off Student Tuition and Fee Balances

African American2 weeks ago

The HistoryMakers Kicks Off Black History Month on PBS

Art3 weeks ago

David Beckham’s luxury men’s grooming brand HOUSE 99 is celebrating its first anniversary

Banking/Financial Services2 weeks ago

Wirecard Enables Mobile Payments via Alipay at Stockmann, the Leading Luxury Fashion Department Store Chain in the Baltics

Automotive3 weeks ago

TrueCar Receives Two “Top Rated” DrivingSales Dealer Satisfaction Awards

Analysis3 weeks ago

750,000+ Celebrate the Future of the Mobility Industry at 2019 NAIAS

Automotive3 weeks ago

Gubagoo Wins “Top Rated” DrivingSales Dealer Satisfaction Award for Fourth Consecutive Year

Food & Beverages4 weeks ago

Plant-Based Foods of Canada Welcomes Canada Food Guide Focus on Plant-based Proteins

Aerospace3 weeks ago

Spotlight Labs Introduces SPYDR® Hypoxia Sensor Device

Advocacy Group Opinion2 weeks ago

Global campaign offers Pope Francis $1 million to try vegan for Lent to save the planet

Corporate Expansion3 weeks ago

Adventure Awaits At Upscale Boutique Hotel Near Rocky Mountain National Park

Europe3 weeks ago

Mytaste Group AB signs agreement with, igaming affiliate supplier voonix.net

Awards3 weeks ago

Don Morphy Wins 2019 Fashion Group International Rising Star Award In Menswear

Acquisitions4 weeks ago

Sentry Energy Solutions Acquires Himarc Environmental Solutions

Food & Beverages3 weeks ago

The Power Of The Bagel: Go Dairy-Free At Einstein Bros. Bagels

Blockchain2 weeks ago

Emmy Nominated, National Geographic filmmaker joins blockchain group PO8

Artificial Intelligence2 weeks ago

Malta AI & Blockchain Summit throwing massive show in May

Amusement Parks and Tourist Attractions 3 weeks ago

Grand Opening of Unique Temple in India

Consumer & Cosmetics3 weeks ago

Show The World Who You Are

Awards2 weeks ago

Corcentric Named a Leader in IDC MarketScape Worldwide SaaS and Cloud-Enabled Accounts Payable Applications 2019

Latest News4 weeks ago

Frist Art Museum introduces “Dorothea Lange: Politics of Seeing”

Awards3 weeks ago

Kaon Interactive Named Top ten provider of sales technology solutions

Africa2 weeks ago

IoT Forum Africa 2019 to Showcase Latest Innovations in IoT

Entertainment2 weeks ago

Chris Evans, new Virgin Radio DJ, looks to follow up his success of CarFest with the launch of RunFestRun

Follow our Tweets

Trending

Please turn AdBlock off